EUCTR2004-000089-11-HU进行中（未招募）不适用
A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Axonyx Inc
- 入组人数
- 560
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Males of at least 50 years of age;
- •Females of at least 50 years of age, who are either at least 2 years post-menopausal or surgically sterile;
- •Probable Alzheimer’s disease consistent with National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria;
- •Have had a computed tomography (CT) or magnetic resonance imaging (MRI) brain scan within the 12 months prior to inclusion in the study that is indicative of probable Alzheimer’s disease;
- •A Mini-Mental State Examination (MMSE) score of between 12 and 24 (inclusive) at Visit 1 (screening);
- •A modified Hachinsky Ischemic Scale (mHIS) score equal to or below 4 at Visit 1 (screening);
- •Reliable caregiver available, and if not living in the same household, caregiver sees patient at least 4 times a week or a total of 15 to 20 hours per week;
- •Patients who do not need continuous nursing care and who are either living at home or in an institutional setting;
- •General health status acceptable for participation in a 6 month clinical study;
- •Is capable of understanding and has given written informed consent [or this has been provided by their acceptable representative (according to local requirements)] and a separate caregiver responsibilities and consent form has also been signed by the patient’s caregiver;
- •Agrees to comply with protocol requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Failure to perform or comply with screening or baseline examinations;
- •Hospitalisation (except for study purposes or due to social reasons, e.g. hospitalisation to unburden the caregiver);
- •Change of concomitant medication 4 weeks prior to screening or during screening period;
- •Participation in another therapeutic clinical study within the 3 months before Visit 2 (baseline);
- •Inability to swallow tablets.
- •Vitamin B12 or folate deficiency unless treated in which case treatment needs to have been stable for 3 months before study entry;
- •Hypothyroidism, defined as any thyroid-stimulating hormone elevation. Corrected hypothyroidism is allowed provided treatment has been stable for 3 months before study entry;
- •Juvenile onset diabetes mellitus;
- •Adult onset diabetes mellitus insufficiently controlled [Haemoglobin A1c (HbA1c) > 8%];
- •A malignancy within the last 5 years;
- •HIV infection;
- •Any history of hepatic insufficiency or abnormal liver enzymes;
- •Renal insufficiency with abnormal serum creatinine outside the age appropriate normal range;
- •Serum electrolytes (sodium, potassium, magnesium) outside the age appropriate normal range;
- •Clinically significant abnormal laboratory values outside the age appropriate normal range;
- •Hypersensitivity to cholinergic drugs;
- •Uncontrolled asthma.
- •Cardiovascular
- •Myocardial infarction or unstable angina within the 6 months prior to Visit 1 (screening);
- •History of more than one myocardial infarction during the last 5 years;
- •Cardiomyopathy;
- •Myocarditis;
- •Severe hypotension;
- •Severe hypertension requiring treatment with more than 2 drugs;
- •Bradycardia (frequency of heart beat < 50/minute);
- •Tachycardia (frequency of heart beat > 90/minute);
- •Presence of AV block (type II / Mobitz II and type III);
- •Congenital long QT syndrome;
- •Sinus node dysfunction;
- •Prolonged QTcB-interval (males > 450 msec; females > 470 msec);
- •Presence of U wave.
- •Psychiatric
- •Axis I diagnosis within 1 year prior to study entry;
- •Previous diagnosis of bipolar affective disorder or schizophrenia;
- •Current alcohol or substance abuse or dependence;
- •Metabolic or toxic encephalopathy or dementia due to a general medical condition;
- •Geriatric Depression Score (GDS) > 5 at Visit 1 (screening).
- •Neurological
- •Stroke within the 6 months prior to Visit 1 (screening) or concomitant with onset of dementia;
- •Tumours, subdural haematoma or other space-occupying processes on CT/MRI;
- •Head trauma with loss of consciousness within 1 year of the onset of dementia;
- •Head trauma with loss of consciousness concurrent with the onset of dementia;
- •Onset of dementia within 1 year following cardiac arrest, surgery with general anaesthetic or resuscitation;
- •Degenerative central nervous system conditions e.g. Huntington’s disease (Huntington’s chorea), Creutzfeld-Jakob disease, Parkinson’s disease, etc.;
- •Genetic cognitive impairment e.g. Trisomy 21 (Down’s syndrome);
- •Wernicke’s encephalopathy;
- •Acute or chronic central nervous system infection including tertiary syphilis;
- •Previous Medication
- •Has previously received:
- •Any acetylcholinesterase inhibitor in the 3 months before study entry;
- 另有 4 项未显示
研究者
相似试验
进行中（未招募）
1 期
Effect of Safinamide on Parkinson’s Disease Related Chronic PaiEUCTR2017-002426-20-ATZambon SpA105
进行中（未招募）
不适用
Study in random distribution of the treatments, one of which is placebo, where neither the Investigator nor the patient knows the study treatment taken by the patient, to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared to placebo on intense itching induced by inhibitors of epidermal growth factor receptor in patients with cancer.Intense pruritus, in oncology subjects, induced by EGFRiMedDRA version: 16.0Level: LLTClassification code 10023084Term: ItchingSystem Organ Class: 100000004858EUCTR2013-002763-25-ITeRRe Therapeutics Ltd
进行中（未招募）
1 期
Effect of Safinamide on Parkinson’s Disease Related Chronic PaiEUCTR2017-002426-20-FRZambon SpA177
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled study to assess the safety and activity of pentosan polysulfate sodium on microvascular blood flow, vascular endothelial injury, and vasoocclusive pain in patients with sickle cell disease - A Study of PPS in Sickle Cell DiseaseSickle cell diseaseEUCTR2008-003573-41-FRTRF Pharma, Inc.100
招募中
不适用
Cyclosporin for moderate to severe alopecia areata and tofacitinib extensioAlopecia areataACTRN12618001084279Sinclair Dermatology38